Literature DB >> 16758251

Radical versus postoperative radiotherapy for localized prostate cancer: a 10-year experience of an academic hospital.

Emilios E Pakos1, Pericles G Tsekeris, Evita J Pitouli, Stergiani P Gritzeli, Evangelos Briasoulis.   

Abstract

This study is a presentation of our department's experience in the treatment of localized prostate cancer with either radical or postoperative radiotherapy (RT). Fifty-five patients with clinical localized prostate cancer were reviewed. Thirty-three patients (T1-T2AN0M0 stage) were treated with radical RT and 22 (T2B-T3N0M0 stage) with postoperative RT. All patients received hormonal therapy. Primary end points of the study were the incidence of clinical and biochemical recurrences and death in the whole group and according to treatment modality. Within a median follow-up of 18 months the overall incidence of clinical relapse was 16.9%, of biochemical relapse 12.7% and of death 10.9%. Both treatment options achieved similar outcomes despite the fact that the patients in the postoperative RT group were of higher stage. Radical RT group tended to have better overall and disease-free survival compared to postoperative RT group, but there was no statistically significant evidence. Long-term toxicity was negligible.

Entities:  

Mesh:

Year:  2006        PMID: 16758251     DOI: 10.1007/s00345-006-0074-2

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  25 in total

Review 1.  Radical radiotherapy for prostate cancer.

Authors:  C C Parker; D P Dearnaley
Journal:  Cancer Treat Rev       Date:  2003-06       Impact factor: 12.111

2.  Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.

Authors:  Ashesh B Jani; Anirban Basu; Ibrahim Abdalla; Phillip P Connell; Lani Krauz; Srinivasan Vijayakumar
Journal:  Am J Clin Oncol       Date:  2003-08       Impact factor: 2.339

3.  A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution.

Authors:  A A Martinez; J A Gonzalez; A K Chung; L L Kestin; M Balasubramaniam; A C Diokno; E L Ziaja; D S Brabbins; F A Vicini
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

4.  Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate.

Authors:  C Catton; M Gospodarowicz; P Warde; T Panzarella; P Catton; M McLean; M Milosevic
Journal:  Radiother Oncol       Date:  2001-04       Impact factor: 6.280

5.  Classification of prostatic carcinomas.

Authors:  D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

6.  Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors.

Authors:  Ashish K Chawla; Harjot K Thakral; Anthony L Zietman; William U Shipley
Journal:  Urology       Date:  2002-05       Impact factor: 2.649

7.  Postprostatectomy radiotherapy for high-risk prostate cancer.

Authors:  Ramona Mayer; Karl Pummer; Franz Quehenberger; Elisabeth Mayer; Lore Fink; Arnulf Hackl
Journal:  Urology       Date:  2002-05       Impact factor: 2.649

8.  (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy.

Authors:  Richard Choo; George Hruby; Julie Hong; Edward Bahk; Eugene Hong; Cyril Danjoux; Gerard Morton; Gerrit DeBoer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-06-01       Impact factor: 7.038

Review 9.  Management of high-risk localized prostate cancer: the integration of local and systemic therapy approaches.

Authors:  Samira Syed; Daniel P Petrylak; Ian M Thompson
Journal:  Urol Oncol       Date:  2003 May-Jun       Impact factor: 3.498

Review 10.  Radiotherapy after prostatectomy.

Authors:  Giuseppe Sanguineti; Paola Franzone; Laura Culp; Michela Marcenaro; Salvina Barra; Vito Vitale
Journal:  Tumori       Date:  2002 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.